a public good project by the
Synthesis
Company
of California

© 2026

Peter J.M. Valk | doi.page

0 works0 citations0 h-index

Peter J.M. Valk

Erasmus MC(NL)University Medical Center(US)Erasmus MC Cancer Institute(NL)

Publications by Year

Research Areas

Acute Myeloid Leukemia Research, Myeloproliferative Neoplasms: Diagnosis and Treatment, Protein Degradation and Inhibitors, Epigenetics and DNA Methylation, Chronic Myeloid Leukemia Treatments

Most-Cited Works

→ Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation(2010)2,713 cited
→ Prognostically Useful Gene-Expression Profiles in Acute Myeloid Leukemia(2004)1,376 cited
→ A 17-gene stemness score for rapid determination of risk in acute leukaemia(2016)896 cited
→ DNA Methylation Signatures Identify Biologically Distinct Subtypes in Acute Myeloid Leukemia(2010)827 cited
→ Molecular Minimal Residual Disease in Acute Myeloid Leukemia(2018)763 cited
→ A Single Oncogenic Enhancer Rearrangement Causes Concomitant EVI1 and GATA2 Deregulation in Leukemia(2014)705 cited

→ 2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party(2021)

681 cited

→ Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance(2005)613 cited

→ Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome(2009)572 cited

→ High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study(2013)446 cited